# Hour 00: 00:00-00:59 - Overnight Low Volume Operations

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 00 represents the beginning of the 24-hour on-demand simulation cycle.
The facility operates at minimal patient volume during this overnight period
with 2 new arrivals and 3 patients carried over from the prior day cycle in
recovery and monitoring status.

## Site Status at 00:00

- Total patients on-site: 5 (3 overnight recovery, 2 new arrivals)
- Active procedures: 0
- Robots in active mode: 0
- Robots in standby mode: 29 (all instances)
- Robots in maintenance: 0
- Queue length: 0 across all stations
- Site safety officer on duty: SSO-N1 (night shift)

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot Needed |
|-----------|------|-----|-----|-------------|-------|------|-------------|
| PAT-ODMND-0001 | 00:12 | 52 | M | NSCLC adenocarcinoma | IIIA | 1 | RT Motion-Tracking (7) |
| PAT-ODMND-0002 | 00:38 | 67 | F | HCC | II | 1 | Imaging (8) |

Patient PAT-ODMND-0001 is a 52-year-old male with Stage IIIA NSCLC
adenocarcinoma presenting for scheduled overnight radiotherapy. He selected
the 00:00-01:00 window via the patient portal due to work schedule conflicts
during daytime hours. ECOG performance status 1. Treatment plan: 2 Gy per
fraction, fraction 12 of 30. Prior fractions delivered at this site.

Patient PAT-ODMND-0002 is a 67-year-old female with Stage II hepatocellular
carcinoma presenting for pre-ablation liver imaging assessment. She selected
an overnight slot to accommodate her caregiver's schedule. ECOG performance
status 1.

## Overnight Recovery Patients (Carried Over)

| Patient ID | Age | Sex | Cancer Type | Status | Since |
|-----------|-----|-----|-------------|--------|-------|
| PAT-ODMND-0003 | 61 | M | Mediastinal tumor | Post-surgical recovery | 22:30 prior day |
| PAT-ODMND-0004 | 44 | F | Soft-tissue sarcoma | Post-biopsy observation | 23:15 prior day |
| PAT-ODMND-0005 | 8 | M | Pediatric ALL | Overnight companion monitoring | 21:00 prior day |

## Active Procedures This Hour

### RT Motion-Tracking Session (00:20-00:38)
- Patient: PAT-ODMND-0001
- Robot: TRACK-01 (RT Motion-Tracking, Instance 1)
- Vault: Radiotherapy Vault 2
- Procedure: Fraction 12 of 30, 2 Gy delivery to left upper lobe lesion
- Duration: 18 minutes (calibration 2 min, treatment 14 min, exit 2 min)
- Beam gating efficiency: 94.2%
- Breathing amplitude: 4.1 mm (within 2-3 mm tolerance after coaching)
- Marker displacement: 1.8 mm average
- Treatment interruptions: 0
- Outcome: Successful completion. Full dose delivered.

Minute-by-minute summary (active procedure):
- 00:20 - Patient positioned, marker block placed on chest
- 00:21 - Calibration complete, breathing pattern established
- 00:22 - Beam-on, first field. Gating active.
- 00:26 - Field 1 complete (1.0 Gy delivered)
- 00:27 - Gantry rotation to field 2
- 00:28 - Beam-on, second field
- 00:32 - Field 2 complete (0.6 Gy delivered)
- 00:33 - Gantry rotation to field 3
- 00:34 - Beam-on, third field
- 00:36 - Field 3 complete (0.4 Gy delivered). Total: 2.0 Gy.
- 00:37 - Marker block removed, patient assisted to seated position
- 00:38 - Patient exits vault. Procedure complete.

### Imaging Assessment (00:45-00:58)
- Patient: PAT-ODMND-0002
- Robot: IMAGE-02 (Imaging Assistant, Instance 2)
- Bay: Imaging Bay 2
- Procedure: Robotic ultrasound liver assessment
- Duration: 13 minutes
- Probe pressure: 1.8 N steady (within 1-3 N range)
- Image quality score: 8.2/10
- Tumor measurement: 34 mm x 28 mm (primary HCC lesion)
- Scan coverage: 92%
- Motion artifact count: 2 (minor, auto-compensated)
- Outcome: Successful. Images uploaded to DICOM server for digital twin
  calibration and ablation planning.

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0004 | 00:25 | Discharged | Post-biopsy observation complete, no complications |

## Adverse Events

None this hour.

## Investigational Drug Administrations

None this hour. (PAT-ODMND-0001 receiving standard-of-care RT only.)

## Site Utilization

- Overall robot utilization: 2.3% (1 of 29 robots active at any given time)
- Queue lengths: 0 across all stations
- Average wait time: 0 minutes (immediate robot availability)
- Robot cleaning cycles: 2 (TRACK-01 post-procedure, IMAGE-02 post-procedure)

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: All procedures conducted in accordance with ethical principles
  and applicable GCP requirements. Overnight operations maintained identical
  safety standards to daytime operations.
- Section 2.9.1: Complete audit trail maintained for RT Motion-Tracking session
  including beam-on times, dose delivery records, and gating efficiency logs.
- Section 4.2.1: Data capture for imaging session included probe pressure
  measurements at 50 Hz, image quality metrics, and tumor measurements with
  synchronized UTC timestamps.

### 21 CFR Part 50 - Adaption
- Section 50.25: Both new patients (PAT-ODMND-0001, PAT-ODMND-0002) had
  previously completed informed consent including Physical AI system
  disclosure, USL readiness scores, and right to non-Physical AI alternatives.
- Section 50.30: Pre-procedure safety matrix completed for both procedures:
  authorization verified, patient identity confirmed, clinical data accessed
  via FHIR, robot readiness confirmed, environmental checks passed.

### 21 CFR Part 312 - Adaption
- Section 312.62: Investigator recordkeeping maintained for all overnight
  patients including Physical AI system interaction logs and vital sign records.
- Section 312.32: Safety reporting systems active and monitoring all patients.
  No reportable events this hour.

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. RT Motion-Tracking Robot TRACK-01 operates on a
platform evaluated at USL scores consistent with the Intermediate band,
reflecting strong simulation switching and AI integration capabilities.
See physical-ai-oncology-trials/unification/usl/paper/usl_oncology_trials.tex.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. PAT-ODMND-0001's ongoing RT course
represents Stage 5-equivalent treatment delivery within a multi-patient,
multi-cancer-type, on-demand operational context.
See physical-ai-oncology-trials/patient-journey/paper/patient_journey_paper.tex.
